U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H39NO2
Molecular Weight 361.5613
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of METHANANDAMIDE

SMILES

CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)N[C@H](C)CO

InChI

InChIKey=SQKRUBZPTNJQEM-FQPARAGTSA-N
InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(26)24-22(2)21-25/h7-8,10-11,13-14,16-17,22,25H,3-6,9,12,15,18-21H2,1-2H3,(H,24,26)/b8-7-,11-10-,14-13-,17-16-/t22-/m1/s1

HIDE SMILES / InChI

Molecular Formula C23H39NO2
Molecular Weight 361.5613
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 4
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 16:31:15 UTC 2023
Edited
by admin
on Fri Dec 15 16:31:15 UTC 2023
Record UNII
F4U8EF3PBH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHANANDAMIDE
Common Name English
5,8,11,14-EICOSATETRAENAMIDE, N-((1R)-2-HYDROXY-1-METHYLETHYL)-, (5Z,8Z,11Z,14Z)-
Systematic Name English
AM-356
Common Name English
(5Z,8Z,11Z, 14Z)-N-((2R)-1-HYDROXYPROPAN-2-YL)EICOSA-5,8,11,14-TETRAENAMIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID70425004
Created by admin on Fri Dec 15 16:31:15 UTC 2023 , Edited by admin on Fri Dec 15 16:31:15 UTC 2023
PRIMARY
WIKIPEDIA
Methanandamide
Created by admin on Fri Dec 15 16:31:15 UTC 2023 , Edited by admin on Fri Dec 15 16:31:15 UTC 2023
PRIMARY
FDA UNII
F4U8EF3PBH
Created by admin on Fri Dec 15 16:31:15 UTC 2023 , Edited by admin on Fri Dec 15 16:31:15 UTC 2023
PRIMARY
PUBCHEM
6321351
Created by admin on Fri Dec 15 16:31:15 UTC 2023 , Edited by admin on Fri Dec 15 16:31:15 UTC 2023
PRIMARY
CAS
157182-49-5
Created by admin on Fri Dec 15 16:31:15 UTC 2023 , Edited by admin on Fri Dec 15 16:31:15 UTC 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
TARGET -> AGONIST